An Observational Study for Evaluation of for the Prevalence of Cerebrotendinous Xanthomatosis (CTX) Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

22 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-10-19

Study Completion Date

2022-06-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The prevalence of CTX in our country is estimated to be 1 / 50.000. The aim of this study is to screen more volunteers by conducting a larger screening from neurology and pediatric metabolism clinics in Turkey.

This observational study was designed retrospectively and prospectively in two stages. In the retrospective section, the patient database and / or patient files will be screened in the neurology and pediatric metabolism clinics and the patients aged 40 and below in the neurology clinics with at least two of the following will be enrolled to the study:

* Ataxia and / or spasticity
* Bilateral cataract (except senile cataract)
* Intellectual limitation
* Non-enhancing hyperintensity on T2 sections in MR imaging of dentate nuclei
* Autosomal recessive transition pattern. (Ex: Relative Marriage)

In the pediatric metabolism centers, cases suspected of CTX and planned to apply the Mignarri Index according to the investigator's opinion will be identified.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Thrombophilia and Thrombosis in Behçet's Disease

NCT06451575

Behçet Disease

RECRUITING

Study Determining the Frequency of Duchenne Muscular Dystrophy and Late-onset Pompe Disease

NCT04120168

Duchenne Muscular Dystrophy Pompe Disease (Late-onset)

COMPLETED

The Serum Sclerostin Levels in Cholesteatoma Patients

NCT03954288

Otitis Media Chronic Cholesteatoma

UNKNOWN

A Study to Evaluate Setanaxib in Patients With Alport Syndrome

NCT06274489

Alport Syndrome

COMPLETED PHASE1/PHASE2

Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome

NCT05845723

Aneurysm Behcet Syndrome, Vascular Type

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

CTX - Cerebrotendinous Xanthomatosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood sampling for cholestanol analysis

Blood sampling will be performed by Düzen Laboratories group for cholestanol

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

I-1. Giving written informed consent

I-2. Patients in neurology clinics should have been identified with at least two of the following:

* Ataxia and / or spasticity
* Bilateral cataract (except senile cataract)
* Intellectual limitation
* Nonintensitive hyperintensity in T2 sections on MRI of the dentate nucleus
* Forming an autosomal recessive transition pattern. (Ex: Relative Marriage)

I-3. In the pediatric metabolism centers, cases suspected of CTX and planned to apply the Mignarri Index according to the investigator's opinion.

I-4. On the day the patient signed the Informed Consent Form, the patient did not get older than 41 years of age (subjects aged 40 and under will be included in the study)

Exclusion Criteria

E-1. The patient's ataxia and / or spasticity, cataract, intellectual limitation, and non-contrasted hyperintensity of T2 sections in MR imaging of dentate nuclei with typical MRI findings are due to a known cause other than CTX or other underlying disease.

E-2. The patient has participated in an interventional clinical study in the last 30 days,

E-3. The patient and / or his / her legal representative does not give consent to participate in the study,

E-4. In the opinion of the investigator, the patient is not able to fulfill the working requirements appropriately,

E-5. Pregnancy and / or lactation

E-6. If the patient was 41 years old when included in the study.

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No